These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 9889031

  • 1. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
    Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E.
    Gynecol Oncol; 1999 Jan; 72(1):60-4. PubMed ID: 9889031
    [Abstract] [Full Text] [Related]

  • 2. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F, Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group.
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [Abstract] [Full Text] [Related]

  • 3. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Apr; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 4. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.
    Clin Cancer Res; 1997 Sep 01; 3(9):1527-33. PubMed ID: 9815839
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
    Hartenbach EM, Harris LS, Bailey HH, Grosen EA, Larrison E, Chen D, Twiggs LB, Schink JC.
    Cancer J Sci Am; 1999 Sep 01; 5(6):348-55. PubMed ID: 10606476
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Oct 15; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 9. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 Oct 15; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M, GRACES Clinical Trial Consortium.
    Gynecol Oncol; 2008 May 15; 109(2):174-81. PubMed ID: 18314182
    [Abstract] [Full Text] [Related]

  • 11. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E, Arbeitsgemeinschaft Gynaekologische Onkologie, Ovarian Cancer Study Group, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    J Clin Oncol; 2006 Mar 01; 24(7):1127-35. PubMed ID: 16505432
    [Abstract] [Full Text] [Related]

  • 12. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study.
    Gebbia V, Blasi L, Borsellino N, Caruso M, Leonardi V, Agostara B, Valenza R.
    Anticancer Res; 2003 Mar 01; 23(1B):765-71. PubMed ID: 12680181
    [Abstract] [Full Text] [Related]

  • 13. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P.
    Gynecol Oncol; 1997 Jan 01; 64(1):109-13. PubMed ID: 8995557
    [Abstract] [Full Text] [Related]

  • 14. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D, Southwest Oncology Group, Gynecologic Oncology Group.
    J Clin Oncol; 2003 Jul 01; 21(13):2460-5. PubMed ID: 12829663
    [Abstract] [Full Text] [Related]

  • 17. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug 01; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.
    Crit Rev Oncol Hematol; 2008 Jun 01; 66(3):229-36. PubMed ID: 18243011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.